Inflammatory Disease Diagnostics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 5.8 billion
Estimated Base Value
2035 Forecast
US$ 11.3 billion
Projected Market Value
CAGR 2026–2035
6.9%
Compound Annual Growth
Largest Segment
Immunoassay based Diagnostics
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
DiaSorin
Emerging Players
Quanterix, Immunovia
Inflammatory Disease Diagnostics Market Overview
The Inflammatory Disease Diagnostics Market includes medical devices and in vitro diagnostic solutions for identifying, assessing, monitoring, and predicting various inflammatory conditions. This market utilizes technologies such as immunoassay-based tests, molecular diagnostics, and point-of-care devices. These tools target specific biomarkers, genetic markers, or physiological changes linked to autoimmune diseases, chronic inflammatory disorders, and acute inflammatory responses. The primary goal is to enable early and accurate diagnosis, guide treatment plans, and track disease progression to improve patient outcomes. Buyers include hospitals, clinical laboratories, and research institutions seeking to enhance diagnostic capabilities.
The Inflammatory Disease Diagnostics Market is estimated at $5.8 Bn in 2025 and is forecast to reach $11.3 Bn by 2035, growing at a CAGR of 6.9% from 2025 to 2035. Market growth is driven by the rising prevalence of chronic inflammatory diseases and an aging global population. Technological advancements that improve diagnostic precision and efficiency also contribute to demand. However, the high cost of advanced diagnostic technologies and the lack of specific biomarkers for certain conditions can limit market adoption.
The market is segmented by Type (Immunoassay Based Diagnostics, Molecular Diagnostics, Clinical Chemistry Diagnostics, Histopathology & Cytology Diagnostics, Flow Cytometry Diagnostics, Point of Care Diagnostics, Genetic Diagnostics), Application (Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis & Psoriatic Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis, Multiple Sclerosis, Vasculitis, Others), End-User (Hospitals, Clinical Laboratories, Diagnostic Centers, Research & Academic Institutions, Physician Offices & Clinics, Home Care Settings, Biotechnology & Pharmaceutical Companies), Component (Instruments & Analyzers, Reagents & Kits, Consumables, Software & Data Management Solutions, Services), Sample Type (Blood Samples, Tissue & Biopsy Samples, Urine Samples, Cerebrospinal Fluid Samples, Stool Samples, Saliva Samples, Synovial Fluid Samples, Others), and Functionality (Quantitative Diagnostics, Qualitative Diagnostics, Screening Diagnostics, Confirmatory Diagnostics, Monitoring Diagnostics). It is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include DiaSorin, QuidelOrtho, QIAGEN, Bio-Rad Laboratories, Werfen, Sysmex, Eurofins Scientific, H.U. Group Holdings, Grifols, Bio-Techne, ELITechGroup, and Seegene. The full report provides detailed analysis of these segments, regional insights, and competitive landscape.
Market Definition & Overview
The Inflammatory Disease Diagnostics Market encompasses medical devices and in vitro diagnostic solutions utilized for the identification, assessment, monitoring, and prognosis of various inflammatory conditions. This market includes a broad spectrum of technologies such as immunoassay-based tests, molecular diagnostics, advanced imaging systems, and point-of-care devices. These diagnostic tools target specific biomarkers, genetic markers, or physiological changes associated with autoimmune diseases, chronic inflammatory disorders, and acute inflammatory responses. The market's primary objective is to facilitate early and accurate diagnosis, guide treatment strategies, and track disease progression for improved patient outcomes.
Scope
- Global geographic coverage across all major regions.
- Focus on medical devices and diagnostic kits for inflammatory conditions.
- Market analysis spans from the 2025 base year to the next 10 years.
Inclusions
- Immunoassay kits for inflammatory biomarkers (e.g., CRP, ESR, ANA).
- Molecular diagnostic tests for genetic predisposition and disease activity.
- Point-of-care testing devices for rapid inflammation detection.
- Specialized imaging equipment used for inflammation assessment.
- Software and bioinformatics tools supporting diagnostic interpretation.
- Consumables and reagents specific to inflammatory disease diagnostics.
Exclusions
- Therapeutic drugs for the treatment of inflammatory diseases.
- General-purpose medical imaging equipment without diagnostic specificity.
- Surgical instruments or interventional medical devices.
- Basic research-use-only (RUO) laboratory reagents.
- Diagnostic testing services offered by clinical laboratories.
Market Size Forecast
Executive Summary
• The Inflammatory Disease Diagnostics market is valued at $5.8 Bn in 2025 and is forecast to reach $11.3 Bn by 2035, reflecting a robust CAGR of 6.9% as demand accelerates across every major segment and region over the ten-year outlook.
• Immunoassay based Diagnostics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The inflammatory disease diagnostics market is witnessing heightened M&A activity, as established players strategically acquire innovators to bolster portfolios and expand global reach in high-growth regional markets.
• Precision medicine and biomarker discovery are catalyzing demand for advanced diagnostic platforms, shifting focus towards earlier, more specific inflammatory disease detection, particularly in autoimmune conditions.
• Evolving global regulatory frameworks, especially within North America and Europe, are accelerating novel point-of-care diagnostic adoption, creating both market entry barriers and strategic opportunities for key players.
• Significant investment flows into AI-driven diagnostic solutions and non-invasive testing methods signal a strategic pivot towards personalized patient management for inflammatory conditions worldwide.
• Supply chain diversification and localized manufacturing strategies are becoming critical competitive differentiators, mitigating geopolitical risks and enabling faster market penetration for diagnostic kits across diverse regions.
• The future landscape features intensified collaboration between diagnostic developers and pharmaceutical companies, integrating companion diagnostics into therapeutic pathways and profoundly reshaping patient care paradigms.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Inflammatory Disease Diagnostics Market was valued at $5.8 billion in the base year.
Robust Growth Outlook
A Compound Annual Growth Rate (CAGR) of 6.9% is projected for the market, indicating strong expansion towards the forecast year.
Significant Future Value
The market is forecast to reach an impressive $11.3 billion by the forecast year.
Market Expansion Drive
The substantial increase from $5.8 billion to $11.3 billion highlights the dynamic growth trajectory of the inflammatory disease diagnostics sector.
Advanced Diagnostics Lead
The advancement in diagnostic technologies, particularly in biomarker identification and point-of-care testing, is a pivotal leading segment driving market growth.
Personalized Medicine Shift
A notable trend driving the market is the increasing adoption of personalized medicine approaches, requiring precise inflammatory disease diagnostics.
Market Dynamics
Market Trends
- Shift towards rapid point-of-care (POC) diagnostic testing is notable.
- Integration of AI and machine learning enhances diagnostic accuracy and speed.
- Non-invasive diagnostic methods are gaining increasing popularity.
- Personalized medicine approaches are driving demand for specific diagnostics.
Growth Drivers
- Rising prevalence of chronic inflammatory diseases fuels market growth.
- Aging global population increases demand for inflammatory disease diagnostics.
- Technological advancements improve diagnostic precision and efficiency.
- Greater awareness leads to earlier diagnosis and treatment initiation.
Restraints
- High cost of advanced diagnostic technologies limits market adoption.
- Lack of specific biomarkers complicates accurate early disease diagnosis.
- Strict regulatory pathways delay market entry for new diagnostic devices.
- Limited reimbursement policies hinder market penetration of novel tests.
Opportunities
- Development of novel biomarkers offers new diagnostic possibilities.
- Expanding into emerging markets presents significant growth avenues.
- Creating cost-effective, rapid, and accessible diagnostic solutions is key.
- Leveraging telehealth for remote monitoring and diagnostics provides new pathways.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Immunoassay Based DiagnosticsMolecular DiagnosticsClinical Chemistry DiagnosticsHistopathology & Cytology DiagnosticsFlow Cytometry DiagnosticsPoint of Care DiagnosticsGenetic Diagnostics |
| By Application | Rheumatoid ArthritisInflammatory Bowel DiseasePsoriasis & Psoriatic ArthritisSystemic Lupus ErythematosusAnkylosing SpondylitisMultiple SclerosisVasculitisOthers |
| By End-User | HospitalsClinical LaboratoriesDiagnostic CentersResearch & Academic InstitutionsPhysician Offices & ClinicsHome Care SettingsBiotechnology & Pharmaceutical Companies |
| By Component | Instruments & AnalyzersReagents & KitsConsumablesSoftware & Data Management SolutionsServices |
| By Sample Type | Blood SamplesTissue & Biopsy SamplesUrine SamplesCerebrospinal Fluid SamplesStool SamplesSaliva SamplesSynovial Fluid SamplesOthers |
| By Functionality | Quantitative DiagnosticsQualitative DiagnosticsScreening DiagnosticsConfirmatory DiagnosticsMonitoring Diagnostics |
Regional Analysis
- North America leads the inflammatory disease diagnostics market due to its robust healthcare infrastructure, high prevalence of chronic inflammatory conditions, and substantial R&D investments. Early adoption of advanced diagnostic technologies and significant healthcare expenditure also propel its dominant market share.
- Asia-Pacific represents the fastest-growing region, fueled by its large patient population, improving healthcare infrastructure, and increasing disposable incomes. Rising awareness about inflammatory diseases and supportive government initiatives in countries like China and India are propelling its rapid market expansion significantly.
- Europe shows a notable trend toward integrating advanced biomarker testing and precision medicine approaches in inflammatory disease diagnostics. This reflects a growing emphasis on personalized treatment strategies and more accurate, early disease detection, driven by strong research funding and regulatory support.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A mature market characterized by high adoption of advanced diagnostic technologies, significant R&D investments, and well-established reimbursement policies for inflammatory disease testing.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiences steady growth fueled by improving healthcare access, rising disposable incomes, increasing awareness of inflammatory diseases, and expanding medical tourism.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Holds a substantial share with its robust healthcare systems, strong regulatory environment, and high awareness of inflammatory conditions, although growth is somewhat moderated compared to emerging regions.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates due to its vast patient population, increasing prevalence of inflammatory diseases, and rapidly developing healthcare infrastructure, particularly in countries like China and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A diverse region showing significant growth, driven by increasing healthcare expenditure, a growing burden of inflammatory and autoimmune disorders, and expanding diagnostic facilities, especially in Gulf nations.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | Largest market driven by high prevalence of autoimmune disorders, significant R&D investment in novel diagnostic technologies, and a robust reimbursement landscape for advanced medical devices. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | The largest economy in South America with a substantial population and increasing healthcare investments, driving demand for accessible inflammatory disease diagnostic solutions. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Leading European market due to high healthcare spending, strong research capabilities in immunology, and rapid adoption of cutting-edge inflammatory disease diagnostic devices. |
| 4 | China | US$ XX.X Mn | XX.X% | Rapidly expanding healthcare infrastructure, a vast patient population, and government initiatives to improve diagnostics are fueling significant growth in inflammatory disease medical devices. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Significant government investment in healthcare infrastructure and increasing prevalence of inflammatory diseases are driving the adoption of advanced diagnostic medical devices. |
Countries Covered (26)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | DiaSorin | XX.X% | Focus on immunodiagnostics and molecular diagnostics through high-throughput automated platforms and a broad test menu. | — | — | LIAISON XLLIAISON XSLIAISON Ixt+1 |
| 2 | QuidelOrtho | XX.X% | Leverage a comprehensive portfolio of diagnostic solutions spanning point-of-care, clinical laboratory, and donor screening to address diverse healthcare needs. | — | — | Sofia 2 Flu+ SARS Antigen FIASavannaVitros XT 7600 Integrated System+1 |
| 3 | QIAGEN | XX.X% | Provide Sample to Insight solutions, integrating sample technologies and assay chemistries with bioinformatics to deliver actionable molecular insights. | — | — | QIAstat-DxQIAcuityRotor-Gene Q+1 |
| 4 | Bio-Rad Laboratories | XX.X% | Innovate and deliver life science research and clinical diagnostic products that advance scientific discovery and improve healthcare outcomes. | — | — | QX200 Droplet Digital PCR SystemBio-Plex Multiplex ImmunoassaysD-10 Hemoglobin A1c Testing System+1 |
| 5 | Werfen | XX.X% | Specializing in Hemostasis, Critical Care, and Autoimmunity diagnostics, offering integrated solutions and services globally. | — | — | ACL TOP Family 50 SeriesGEM Premier 5000ILab Ares+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
DiaSorin, QuidelOrtho, QIAGEN, Bio-Rad Laboratories, Werfen, Sysmex, Eurofins Scientific, H.U. Group Holdings, Grifols, Bio-Techne, ELITechGroup, Seegene, Stratec Biomedical, Trinity Biotech, AESKU Group, Orgentec Diagnostica, Exagen Inc., Theradiag, ZEUS Scientific, Vela Diagnostics
The global Inflammatory Disease Diagnostics market features a competitive landscape led by DiaSorin, QuidelOrtho, QIAGEN, Bio-Rad Laboratories, Werfen, and Sysmex, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
DiaSorin
QuidelOrtho
QIAGEN
Bio-Rad Laboratories
Werfen
Sysmex
Eurofins Scientific
H.U. Group Holdings
Grifols
Bio-Techne
ELITechGroup
Seegene
Stratec Biomedical
Trinity Biotech
AESKU Group
Orgentec Diagnostica
Exagen Inc.
Theradiag
ZEUS Scientific
Vela Diagnostics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Innovative AI-Powered Platform Launched for Early Inflammatory Disease Detection
A prominent diagnostics company introduced an advanced AI-driven platform designed to analyze complex biomarker patterns for earlier and more accurate diagnosis of various inflammatory conditions, promising improved patient stratification and treatment efficacy.
Global Diagnostics Leader Acquires Specialist in Point-of-Care Inflammatory Testing
A major medical device conglomerate completed the acquisition of a startup renowned for its rapid, portable diagnostic tests for key inflammatory markers, significantly enhancing its point-of-care diagnostics portfolio and market presence in chronic inflammatory disease management.
Strategic Partnership Formed for Inflammatory Disease Companion Diagnostics Development
A leading diagnostics firm announced a collaborative agreement with a pharmaceutical giant to co-develop companion diagnostics for a pipeline of novel inflammatory disease therapeutics, aiming to personalize medicine and optimize treatment outcomes for patients.
Substantial Investment Secured for Next-Generation Inflammatory Biomarker Discovery
A cutting-edge biotech company focused on novel biomarker research received significant venture capital funding to accelerate the development of its proprietary platform for identifying and validating new diagnostic targets in systemic inflammatory diseases, potentially revolutionizing early detection.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $5.8 Bn |
| Market Size (Forecast) | $11.3 Bn |
| CAGR | 6.9% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 26 Countries |
| Segments Covered | 6 Segments, 40 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Inflammatory Disease Diagnostics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Inflammatory Disease Diagnostics market is estimated at $5.8 Bn in 2025. It is forecast to reach $11.3 Bn by 2035.
The Inflammatory Disease Diagnostics market is forecast to grow at a CAGR of 6.9% from 2025 to 2035.
The main segments include Immunoassay Based Diagnostics, Molecular Diagnostics, Clinical Chemistry Diagnostics, Histopathology & Cytology Diagnostics, Flow Cytometry Diagnostics, Point of Care Diagnostics, Genetic Diagnostics by Type. Applications cover Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis & Psoriatic Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis, Multiple Sclerosis, Vasculitis, and others.
Leading companies in the Inflammatory Disease Diagnostics market include DiaSorin, QuidelOrtho, QIAGEN, Bio-Rad Laboratories, Werfen, Sysmex, Eurofins Scientific, H.U. Group Holdings, Grifols, Bio-Techne, ELITechGroup, and Seegene.
The report covers market size and growth, segmentation by type, application, end-user, component, sample type, and functionality, and regional analysis. It also includes insights into market drivers, restraints, and the competitive landscape with profiles of leading companies.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Kidney Disease Diagnostics Market
$214.0 Mn in 2025 · 18.8% CAGR
Infectious Disease Diagnostics Market
$38.5 Bn in 2025 · 6.5% CAGR
Rare Disease Diagnostics Market
$3.4 Bn in 2025 · 16.5% CAGR
Advanced Molecular Diagnostics Market
$14.6 Bn in 2025 · 16.2% CAGR
AI Diagnostics Market
$2.1 Bn in 2025 · 16.3% CAGR
AI Genomic Diagnostics Market
$800.1 Mn in 2025 · 24.0% CAGR
AI Neurology Diagnostics Market
$731.0 Mn in 2025 · 18.5% CAGR
AI Precision Diagnostics Engine Market
$448.0 Mn in 2025 · 21.7% CAGR